INCY - Incyte Corporation (INCY) Q4 2023 Earnings Call Transcript
2024-02-13 12:37:03 ET
Incyte Corporation (INCY)
Q4 2023 Earnings Conference Call
February 13, 2024, 08:00 AM ET
Company Participants
Ben Strain - Associate Vice President, Investor Relations
Hervé Hoppenot - Chief Executive Officer
Barry Flannelly - General Manager, North America
Pablo Cagnoni - President, Head of Research & Development
Steven Stein - Chief Medical Officer
Christiana Stamoulis - Chief Financial Officer
Conference Call Participants
Kripa Devarakonda - Truist Securities
Andrew Berens - Leerink
Michael Schmidt - Guggenheim
Vikram Purohit - Morgan Stanley
Derek Archila - Wells Fargo
David Lebowitz - Citi
Jessica Fye - JPMorgan
Tazeen Ahmad - Bank of America
Marc Frahm - TD Cowen
Ren Benjamin - Simpsons JMP
Matt Phipps - William Blair
Presentation
Operator
Hello, and welcome to the Incyte Fourth Quarter Earnings Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.
It's now my pleasure to turn the call over to Ben Strain, Associate Vice President, Investor Relations. Please go ahead, Ben.
Ben Strain
Thank you, Kevin. Good morning, and welcome to Incyte's fourth quarter 2023 earnings conference call.
Before we begin, I encourage everyone to go to the Investors section of our website to find the press release, related financial tables and slides that follow today's discussion.
On today's call, I'm joined by Hervé, Barry, Pablo, Steven and Christiana, who will deliver our prepared remarks and will participate in the Q&A.
I would like to point out that we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties and our actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings for additional detail.
I will now hand the call over to Hervé.
Hervé Hoppenot
Thank you, Ben, and good morning, everyone.
So, on Slide 5, we achieved another strong year with 2023 product and royalty revenues growing 14% versus 2022 to reach $3.7 billion, continuing the strong performance we have delivered since 2018. We also achieved [a symbolic] (ph) milestone in the fourth quarter. Total product and royalty revenue reached $1 billion quarterly for the first time, driven by the continued growth of Jakafi and successful launch of Opzelura....
Incyte Corporation (INCY) Q4 2023 Earnings Call Transcript